US Patent

US10300041 — Liquid oral simvastatin compositions

Formulation · Assigned to Rosemont Pharmaceuticals Ltd · Expires 2027-04-26 · 1y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a liquid oral simvastatin composition with specific particle size and concentration requirements.

USPTO Abstract

Aqueous suspensions for oral administration are disclosed that include simvastatin having a d 90 of simvastatin particles of less than about 100 μm as the active agent. The aqueous suspension also includes simvastatin as about 20 mg to about 80 mg per 5 ml of the aqueous suspension, a suspending agent as about 20 mg to about 50 mg of the aqueous suspension, a wetting agent, an antimicrobial preservative, an antifoaming agent, water, and a buffering system providing the aqueous suspension with a pH of about 6.4 to about 7. Methods of making such a suspension and methods of treatments in orally administering the same are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US10300041
Jurisdiction
US
Classification
Formulation
Expires
2027-04-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Rosemont Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.